Proposed Collection; Comment Request; Follow-Up of Kidney Cancer Patients From the Central European Multicenter Case-Control Study, 65387-65388 [E8-26086]
Download as PDF
<![CDATA[
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
of the Food and Drug Administration
(FDA). At least one portion of the
meeting will be closed to the public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 20, 2008, from 1 p.m.
to approximately 4 p.m.
Location: National Institutes of
Health, Building 29B, Conference Room
C. This meeting will be held by
teleconference. The public is welcome
to attend the meeting at the specified
location where a speakerphone will be
provided. Public participation in the
meeting is limited to the use of the
speakerphone in the conference room.
Important information about
transportation and directions to the NIH
campus, parking, and security
procedures is available on the Internet
at https://www.nih.gov/about/visitor/
index.htm. Visitors must show two
forms of identification, one of which
must be a government-issued photo
identification such as a Federal
employee badge, driver’s license,
passport, green card, etc. Detailed
information about security procedures is
located at https://www.nih.gov/about/
visitorsecurity.htm. Due to the limited
available parking, visitors are
encouraged to use public transportation.
Contact Person: Christine Walsh or
Denise Royster, Center for Biologics
Evaluation and Research (HFM–71),
Food and Drug Administration, 1401
Rockville Pike. Rockville, MD 20852,
301–827–0314, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), code
3014512391. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On November 20, 2008, the
Committee will meet in open session to
hear updates of the research program in
the Laboratory of DNA Viruses, Division
of Viral Products, Center for Biologics
Evaluation and Research, FDA.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2008 and scroll down to the
appropriate advisory committee link.
Procedure: On November 20, 2008,
from 1 p.m. to approximately 3:30 p.m.,
the meeting is open to the public.
Interested persons may present data,
information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
November 13, 2008. Oral presentations
from the public will be scheduled
between approximately 2:30 p.m. and
3:30 p.m. Those desiring to make formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 5, 2008. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 6, 2008.
Closed Committee Deliberations: On
November 20, 2008, from approximately
3:30 p.m. to 4 p.m. the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The
committee will discuss the report of the
intramural research program and make
recommendations regarding personnel
staffing decisions.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Christine
Walsh or Denise Royster at least 7 days
in advance of the meeting.
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
65387
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Dated: October 21, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–26139 Filed 10–31–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Follow-Up of Kidney Cancer
Patients From the Central European
Multicenter Case-Control Study
SUMMARY: In compliance with the
requirement of section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI), the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: Follow-up
of Kidney Cancer Patients from the
Central European Multicenter CaseControl Study. Type of Information
Collection Request: New. Need and Use
of Information Collection: The purpose
of this questionnaire is to obtain
information on the 5-year survival status
of kidney cancer patients that were
enrolled in a Central European CaseControl Study of Kidney Cancer that
was conducted between 2001–2004. The
aim is to assess survival, the prevalence
of recurrent disease and progression,
and to investigate patient, tumor and
genetic determinants of survival among
cases. The questionnaire will collect
information on patient related factors,
tumor related factors not collected
during the initial study, and the type of
treatment(s) received since the patients
were last contacted for the case-control
study. This questionnaire adheres to
The Public Health Service Act, section
412 (42 U.S.C. 285a–1) and section 413
(42 U.S.C. 285a–2), which authorizes
the Division of Cancer Epidemiology
and Genetics of the National Cancer
Institute (NCI) to establish and support
programs for the detection, diagnosis,
prevention and treatment of cancer; and
to collect, identify, analyze and
disseminate information on cancer
research, diagnosis, prevention and
E:\FR\FM\03NON1.SGM
03NON1
65388
Federal Register / Vol. 73, No. 213 / Monday, November 3, 2008 / Notices
treatment. Frequency of Response:
Once. Affected Public: Individuals. Type
of Respondents: Individuals that had
previously participated in the Central
European Renal Cancer Case-Control
Study between 2001–2004 and
physician abstractors. The estimated
total annual burden hours requested is
296. The annualized cost to respondents
is estimated at $5174. There are no
additional capital costs, operating costs,
and/or maintenance costs to report.
TABLE 1—ESTIMATES OF ANNUAL BURDEN HOURS
Average
time per
response
(minutes/
hour)
Annual
burden
hours
Number of
respondents
Frequency
of response
Patients ............................................................................................................................
Families (NOK) ................................................................................................................
Physicians ........................................................................................................................
200
240
10
1
1
1
40/60
40/60
15/60
133.33
160.00
2.50
Totals ........................................................................................................................
450
....................
....................
295.83
Type of respondents
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Lee E. Moore, PhD,
MPH, Investigator/Epidemiologist,
Occupational and Environmental
Epidemiology Branch, Division of
Cancer Epidemiology and Genetics,
National Cancer Institute, NIH, DHHS,
Executive Plaza South, Room 8102,
6120 Executive Blvd., EPS–MSC 7240,
Bethesda, MD 20892–7270 or call nontoll-free number 301–496–6427 or email your request, including your
address to: moorele@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
sroberts on PROD1PC70 with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Aug<31>2005
16:58 Oct 31, 2008
Jkt 217001
Dated: October 24, 2008.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison Office,
National Institutes of Health.
[FR Doc. E8–26086 Filed 10–31–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Review of
KNOD and NAME Member Conflicts.
Date: November 20, 2008.
Time: 9 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Elisabeth Koss, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3152,
MSC 7770, Bethesda, MD 20892, (301) 435–
1721, kosse@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Shared
Instrumentation.
Date: November 20–21, 2008.
Time: 8 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: David Balasundaram, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5189,
MSC 7840, Bethesda, MD 20892, 301–435–
1022, balasundaramd@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: AIDS and Related
Research Integrated Review Group AIDS
Molecular and Cellular Biology Study
Section.
Date: November 24, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Fairmont Hotel, 2401 M Street,
NW., Washington, DC 20037.
Contact Person: Kenneth A. Roebuck, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5214,
MSC 7852, Bethesda, MD 20892, (301) 435–
1166, roebuckk@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Aging
Program Project Review.
Date: November 24–25, 2008.
Time: 8 a.m. to 8 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive,, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Seetha Bhagavan, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1126,
MSC 7846, Bethesda, MD 20892, (301) 435–
1121, bhagavas@csr.nih.gov.
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 73, Number 213 (Monday, November 3, 2008)]
[Notices]
[Pages 65387-65388]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-26086]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; Follow-Up of Kidney Cancer
Patients From the Central European Multicenter Case-Control Study
SUMMARY: In compliance with the requirement of section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Cancer Institute
(NCI), the National Institutes of Health (NIH) will publish periodic
summaries of proposed projects to be submitted to the Office of
Management and Budget (OMB) for review and approval.
Proposed Collection: Title: Follow-up of Kidney Cancer Patients
from the Central European Multicenter Case-Control Study. Type of
Information Collection Request: New. Need and Use of Information
Collection: The purpose of this questionnaire is to obtain information
on the 5-year survival status of kidney cancer patients that were
enrolled in a Central European Case-Control Study of Kidney Cancer that
was conducted between 2001-2004. The aim is to assess survival, the
prevalence of recurrent disease and progression, and to investigate
patient, tumor and genetic determinants of survival among cases. The
questionnaire will collect information on patient related factors,
tumor related factors not collected during the initial study, and the
type of treatment(s) received since the patients were last contacted
for the case-control study. This questionnaire adheres to The Public
Health Service Act, section 412 (42 U.S.C. 285a-1) and section 413 (42
U.S.C. 285a-2), which authorizes the Division of Cancer Epidemiology
and Genetics of the National Cancer Institute (NCI) to establish and
support programs for the detection, diagnosis, prevention and treatment
of cancer; and to collect, identify, analyze and disseminate
information on cancer research, diagnosis, prevention and
[[Page 65388]]
treatment. Frequency of Response: Once. Affected Public: Individuals.
Type of Respondents: Individuals that had previously participated in
the Central European Renal Cancer Case-Control Study between 2001-2004
and physician abstractors. The estimated total annual burden hours
requested is 296. The annualized cost to respondents is estimated at
$5174. There are no additional capital costs, operating costs, and/or
maintenance costs to report.
Table 1--Estimates of Annual Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
time per Annual
Type of respondents Number of Frequency response burden
respondents of response (minutes/ hours
hour)
----------------------------------------------------------------------------------------------------------------
Patients.................................................... 200 1 40/60 133.33
Families (NOK).............................................. 240 1 40/60 160.00
Physicians.................................................. 10 1 15/60 2.50
---------------------------------------------------
Totals.................................................. 450 ........... ........... 295.83
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Evaluate whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) Evaluate the accuracy of the agency's estimate of the
burden of the proposed collection of information, including the
validity of the methodology and assumptions used; (3) Enhance the
quality, utility, and clarity of the information to be collected; and
(4) Minimize the burden of the collection of information on those who
are to respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the data collection plans and
instruments, contact Lee E. Moore, PhD, MPH, Investigator/
Epidemiologist, Occupational and Environmental Epidemiology Branch,
Division of Cancer Epidemiology and Genetics, National Cancer
Institute, NIH, DHHS, Executive Plaza South, Room 8102, 6120 Executive
Blvd., EPS-MSC 7240, Bethesda, MD 20892-7270 or call non-toll-free
number 301-496-6427 or e-mail your request, including your address to:
moorele@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Dated: October 24, 2008.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison Office, National Institutes of Health.
[FR Doc. E8-26086 Filed 10-31-08; 8:45 am]
BILLING CODE 4140-01-P
